Date: 2018-10-09
Type of information: Licensing agreement
Compound: CRISPR/Cas9 genome editing technology patents
Company: ERS Genomics (Ireland) GenAhead Bio (Japan)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: genome editing
Disease:
Details:
- • On October 9, 2018, GenAhead Bio and ERS Genomics announced a non-exclusive license agreement to provide GenAhead with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology.
- GenAhead had its start in April of this year and seeks to build a world class genome editing service business. Located in Fujisawa City, GenAhead uses its expertise in gene delivery combined with state of the art CRISPR/Cas9 technology to offer a highly efficient and accurate platform for genome editing. Summit Pharmaceuticals International Corporation, the licensing partner of ERS Genomics in Japan, provided key support in putting this agreement in place.
- GenAhead Bio is a new spinout biotechnology company focused on genome editing and nucleic acid delivery. The headquarters are located in Shonan Health Innovation Park (iPark), in Fujisawa, Japan, which was launched by Takeda Pharmaceutical Company Limited by transforming its Shonan Research Institute to enhance scientific innovation. Through a licensing deal with ERS Genomics, GenAhead Bio has launched CRISPR/Cas9 services to leading pharmaceutical companies and academics to produce cells with precise genetic modifications utilizing high KI efficiency, such as single nucleotide polymorphism (SNP) conversions as a cellular disease model, in any particular mammalian cell line. Regarding induced pluripotent stem (iPS) cells, GenAhead Bio has partnered with ReproCELL Inc., a pioneering company in iPS cell technologies, to deliver GenAhead Bio’s products more expeditiously to the customers in the world. GenAhead Bio has another technology; delivery of nucleic acids to skeletal muscle and heart. It is also applicable to immune cells. In addition to fee-for service, GenAhead Bio envisions a future of research and development partnership with pharmaceutical companies in both fields.
Financial terms:
Latest news:
Is general: Yes
